TD Cowen on Medtronic, Inc. (MDT): 'We believe the results should be enough to sustain recent multiple expansion'

Go back to TD Cowen on Medtronic, Inc. (MDT): 'We believe the results should be enough to sustain recent multiple expansion'

Needham on Medtronic, Inc. (MDT): 'We believe that MDT is in the early stages of a strong product cycle'

September 1, 2026 1:27 PM EDT

Needham analyst Michael Matson reiterated a Buy rating and $114.00 price target on Medtronic, Inc. (NYSE: MDT).

The analyst comments "MDT's F1Q27 revenue and EPS beat consensus, and management raised FY27 revenue and EPS guidance. Organic growth improved to 7.0%... More